Duloxetine Capsule, Delayed Release
Product Images NDC 0615-8495

Product Visual Gallery

This gallery contains 13 technical images submitted to the FDA as part of the official labeling for Duloxetine (NDC 0615-8495). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Ncs Healthcare Of Ky, Llc Dba Vangard Labs, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Structure (Duloxetine Dr Caps 8494 8495 8496 1)

Chemical structure of duloxetine hydrochloride, depicting the molecular arrangement of atoms including a thiophene ring, a naphthalene moiety, and an amine group with hydrochloride salt.*

FDA Label Image

Figure 10 (Duloxetine Dr Caps 8494 8495 8496 10)

A line graph comparing the percentage of patients improved against the percent improvement in pain from baseline (BOCF) for Duloxetine 60/120 mg once daily versus placebo. The graph shows two curves representing patient response rates, with the horizontal axis indicating pain improvement percentages and the vertical axis showing the percentage of patients improved. Vertical dashed lines mark specific improvement intervals.*

FDA Label Image

Principal Display Panel (20 MG)

Label for Duloxetine delayed-release capsules 20 mg by NCS HealthCare of KY, LLC dba Vangard Labs. The label includes lot and expiration placeholders, a quantity of 30 capsules, and specifies storage at controlled room temperature. Multiple smaller barcode labels with the same product details for institutional use are also shown, packaged by Vangard in Glasgow, KY.*

FDA Label Image

Principal Display Panel (30 MG)

The image shows a packaging label for Duloxetine delayed-release capsules USP 30 mg. The label includes barcodes, lot number 8495-, quantity of 30 capsules, and storage instructions to keep at 20°-25°C. It specifies dispensing in a tight container and notes the dosage strength equivalence. The labeler is NCS HealthCare of KY, LLC dba Vangard Labs with manufacturing by Lupin. Multiple small labels with the same information and barcodes are printed on the right side.*

FDA Label Image

Principal Display Panel (60 MG)

Duloxetine Delayed-release Capsule USP 60 mg label showing the drug name, dosage form, strength, lot number, and quantity of 30 capsules. The label indicates the drug is manufactured by Lupin and packaged by Vanguard Labs in Glasgow, KY. It includes storage instructions (20-25°C), barcode, and notice for institutional use only.*

FDA Label Image

Figure 1 (Duloxetine Dr Caps 8494 8495 8496 2)

A Kaplan-Meier curve comparing the proportion of patients with relapse over time (days) between Duloxetine treatment and placebo groups. The graph shows two lines, with the Duloxetine group exhibiting a lower proportion of relapse compared to placebo over approximately 200 days.*

FDA Label Image

Figure 2 (Duloxetine Dr Caps 8494 8495 8496 3)

A Kaplan-Meier curve chart comparing the proportion of patients with relapse over time in days from randomization. The chart shows two lines representing treatment with Duloxetine and placebo, illustrating relapse rates over approximately 250 days.*

FDA Label Image

Figure 1 (Duloxetine Dr Caps 8494 8495 8496 4)

A line graph showing the percentage of patients improved versus percent improvement in pain from baseline. It compares four groups: Duloxetine 60 mg twice daily (BID), Duloxetine 60 mg once daily (QD), Duloxetine 20 mg QD, and placebo. The y-axis represents the percentage of patients improved, and the x-axis represents percent improvement in pain from baseline.*

FDA Label Image

Figure 2 (Duloxetine Dr Caps 8494 8495 8496 5)

A line graph showing the percentage of patients improved versus percent improvement in pain from baseline. The graph compares three groups: Duloxetine 60 mg BID, Duloxetine 60 mg QD, and placebo, illustrating how patient improvement varies with increasing pain relief percentages.*

FDA Label Image

Fig 5 (Duloxetine Dr Caps 8494 8495 8496 6)

A line graph showing the percentage of patients improved by percent improvement in pain from baseline. It compares three groups: Duloxetine 60 mg twice daily, Duloxetine 60 mg once daily, and placebo. The x-axis represents percent improvement in pain, and the y-axis represents the percentage of patients improved, with the graph illustrating higher improvement percentages for Duloxetine treatments versus placebo.*

FDA Label Image

Fig 6 (Duloxetine Dr Caps 8494 8495 8496 7)

A line graph showing the percentage of patients improved versus the percent improvement in pain from baseline for different Duloxetine dosages and placebo. Four lines represent Duloxetine 120 mg twice daily, Duloxetine 60 mg once daily (two different series), and placebo, charting patient improvement at various pain reduction thresholds.*

FDA Label Image

Figure 8 (Duloxetine Dr Caps 8494 8495 8496 8)

A line graph showing the percentage of patients improved versus percent improvement in pain from baseline. It compares patients treated with Duloxetine 60/120 mg once daily to those given a placebo, illustrating higher improvement rates with Duloxetine across various pain improvement thresholds.*

FDA Label Image

Figure 9 (Duloxetine Dr Caps 8494 8495 8496 9)

A line graph comparing the percentage of patients improved over varying percent improvements in pain from baseline (BOCF) between a placebo and Duloxetine 60 mg once daily. The x-axis shows percent improvement in pain from 0 to 100, and the y-axis shows the percentage of patients improved from 0% to 100%. Two lines represent the placebo group and the Duloxetine 60 mg group, indicating higher patient improvement rates with Duloxetine across the pain improvement spectrum.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.